PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
Reem Saleh, Rowaida Z Taha, Varun Sasidharan Nair, Nehad M Alajez, Eyad Elkord
Cancers | MDPI | Published : 2019
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, which shows resistance to common breast cancer therapies, as it lacks the expression of the most common breast cancer targets. Therefore, TNBC treatment remains a challenge. Targeting programmed cell death-ligand 1 (PD-L1) by monoclonal antibodies (mAbs), for example, atezolizumab, has revolutionized the treatment for various cancer types. However, the therapeutic efficacy of targeting PD-L1 in TNBC is currently under investigation. In this study, we investigated the molecular mechanisms by which the human TNBC cell line MDA-MB-231, expressing PD-L1, responds to atezolizumab, using RNA-Seq. Transcriptome analy..View full abstract
Awarded by Qatar Biomedical Research Institute, Qatar Foundation
This research was funded by Qatar Biomedical Research Institute, Qatar Foundation, grant number: VR04.